文章摘要
莫文娟.抗感染药不良反应现状及风险防控措施探讨[J].中国药事,2019,33(5):586-593
抗感染药不良反应现状及风险防控措施探讨
Discussion on Current Status of Adverse Drug Reactions of Anti-infectives and Risk Prevention and Control Measures
投稿时间:2018-11-08  
DOI:10.16153/j.1002-7777.2019.05.015
中文关键词: 抗感染药  药品不良反应  风险防控
英文关键词: anti-infectives  adverse drug reaction  risk prevention and control
基金项目:
作者单位
莫文娟 昆山市药品监督管理所, 昆山市药品不良反应监测中心, 昆山 215300 
摘要点击次数: 27
全文下载次数: 23
中文摘要:
      目的:分析抗感染药不良反应现状,探析风险防控措施,为降低抗感染药用药风险提供参考。方法:采用回顾性研究方法,对昆山市2015年-2017年药品不良反应监测网络收到的抗感染药不良反应报告进行总结。结果:3年中抗感染药不良反应报告平均占同期报告总数的47.97%,新的和严重不良反应报告平均占20.87%。抗感染药不良反应报告主要来自静脉注射给药,占84.72%。医疗机构为主要上报单位的报告占90.83%。结论:应进一步规范临床合理用药,严格落实企业主体责任,修订完善配套法规,拓宽不良反应监测模式,全方位健全不良反应监测体系,以有效降低抗感染药不良反应的发生。
英文摘要:
      Objective:To analyze the current status of the adverse drug reactions (ADR) of anti-infectives and the corresponding risk prevention and control measures and to provide references for reducing the medication risks of anti-infectives. Methods:A retrospective study was conducted to summarize the ADR reports received by ADR monitoring network in Kunshan from 2015 to 2017. Results:In the past 3 years, the reports of the ADR of the anti-infectives accounted for an average of 47.97% of the total number received in the same period, and the new and serious ADR accounted for an average of 20.87%. Most of the ADR of anti-infectives were due to intravenous injection, accounting for 84.72% and medical institutions were the major units, accounting for 90.83%. Conclusion:Clinical rational drug use should be further standardized. The primary responsibility of manufacturers should be strictly implemented. The laws and regulations should be revised and improved. The monitoring mode of ADR should be broadened. The monitoring system of ADR should be comprehensively improved in order to effectively reduce the ADR of anti-infectives.
查看全文   查看/发表评论  下载PDF阅读器
关闭